Abstract
Breast cancer (BC) in patients with germline mutations ofBRCA1/BRCA2are associated with benefit from drugs targeting DNA damage response (DDR), but they account for only 5–7% of overall breast cancer. To define the characteristics of these tumors and also to identify tumors without BRCA mutation but with homologous recombination deficiency (HRD) is clinically relevant. To define characteristic features of HRD tumors and analyze the correlations betweenBRCA1/BRCA2and BC subtypes, we analyzed 981 breast tumors from the TCGA database using the signature analyzer. The BRCA signature was strongly associated with the HRD score top 10% (score ≥ 57) population. This population showed a high level of mutations in DDR genes, includingBRCA1/BRCA2. HRD tumors were associated with high expression levels ofBARD1andBRIP1. Besides,BRCA1/2 mutations were dominantly observed in basal and luminal subtypes, respectively. A comparison of HRD features in BC revealed thatBRCA1exerts a stronger influence inducing HRD features thanBRCA2does. It reveals genetic differences betweenBRCA1andBRCA2and provides a basis for the identification of HRD and other BRCA-associated tumors.
Funding Information
  • Korea Health Industry Development Institute (HI14C1277)

This publication has 58 references indexed in Scilit: